CVS Health Corporation — FY2016 Form 10-K
Reporting period: Fiscal year ended December 31, 2016. Although the request metadata refers to 2016 Q4, this is an annual filing; the supplied text does not provide standalone fourth-quarter financial results. The filing incorporates the full MD&A and financial statements from CVS Health’s 2016 Annual Report to Stockholders, which are not included in the supplied text.
Business context
CVS Health operates Pharmacy Services, Retail/LTC and Corporate segments. Its integrated business includes a large pharmacy-benefit manager, retail pharmacies, specialty and mail-order pharmacies, long-term-care pharmacy services, and MinuteClinic locations. In 2016 it managed or filled approximately 1.2 billion prescriptions in each of its Pharmacy Services and Retail/LTC segments. Aetna represented approximately 11.2% of consolidated revenue, making it a significant customer concentration.
Financial results and key metrics
| Metric | FY2016 | FY2015 | Change |
|---|---|---|---|
| Net revenue | $177.526 billion | $153.290 billion | +15.8% |
| Gross profit | $28.857 billion | $26.528 billion | +8.8% |
| Operating profit | $10.338 billion | $9.454 billion | +9.3% |
| Net income attributable to CVS Health | $5.317 billion | $5.237 billion | +1.5% |
| Diluted EPS | $4.90 | $4.63 | +5.8% |
| Net interest expense | $1.058 billion | $838 million | +26.3% |
| Long-term debt at year-end | $25.615 billion | $26.267 billion | −2.5% |
| Cash dividends per share | $1.70 | $1.40 | +21.4% |
Approximate calculated margins: gross margin was 16.3% versus 17.3%; operating margin was 5.8% versus 6.2%; and net margin was 3.0% versus 3.4%. Revenue rose substantially faster than gross profit and operating profit, while higher interest expense and a $643 million loss on early extinguishment of debt weighed on earnings. The filing excerpt does not provide cash flow amounts, cash balances, current liabilities, or a clear liquidity measure.
At year-end, total assets were $94.462 billion and shareholders’ equity was $36.834 billion. CVS repurchased 47.5 million shares for approximately $4.5 billion during 2016. The annual dividend increased to $1.70 per share from $1.40.
Material changes versus prior year
- Revenue increased 15.8%, with the comparison affected by the 2015 acquisitions of Omnicare and Target’s pharmacies and clinics.
- Gross profit and operating profit grew more slowly than revenue; calculated margins declined year over year.
- Net income attributable to CVS Health rose only 1.5%, despite higher operating profit; interest expense increased and the company recorded a $643 million debt-extinguishment loss, compared with none in 2015.
- Long-term debt was modestly lower than in 2015. The company completed acquisition integration for relevant internal controls during the fourth quarter of 2016.
Outlook, risks and unusual items
- Guidance: The supplied filing text does not provide a clear quantified earnings or revenue forecast. Management’s full MD&A and forward-looking statement are incorporated by reference but are not reproduced here.
- Management and policy uncertainty: CVS cited uncertainty following the 2016 U.S. elections, including potential changes to the ACA, Medicaid, tax and trade policies. It stated that the effects were not yet predictable.
- Reimbursement and margins: The company highlighted PBM, retail pharmacy and long-term-care margin pressure from pricing competition, client demands, reimbursement changes, generic-drug pricing and shifts in prescription mix.
- Regulatory exposure: Risks include extensive federal and state healthcare rules, Medicare Part D requirements, audits, pharmacy licensing, controlled-substance oversight, privacy and cybersecurity obligations, and possible changes to PBM regulation.
- 2017 reimbursement item: The 21st Century Cures Act changed Medicare Part B durable medical equipment infused-drug payment benchmarks effective January 1, 2017. CVS expected the overall impact to be negative, but said the full effect was uncertain.
- Other risks: The filing identifies client retention and contract renewals, restricted pharmacy networks, acquisition integration, supplier and drug availability, information-system disruption, litigation, and debt-service flexibility as material risks.
- Contingency: CVS was negotiating with the EPA and Department of Justice over alleged historical hazardous-waste noncompliance at three Puerto Rico pharmacy locations; the filing says the matter was not material to the business or financial position.
Investor verification priorities
- Review the incorporated annual-report MD&A, audited financial statements and notes for operating cash flow, capital expenditure, cash and short-term borrowings, liquidity, debt maturities, and segment-level results.
- Assess whether revenue growth from the Omnicare and Target acquisitions translated into sustainable organic growth and improved margins.
- Verify the status and economics of the Aetna relationship, which generated 11.2% of 2016 consolidated revenue.
- Track pharmacy reimbursement and PBM pricing pressures, Medicare Part D developments, and the actual impact of the Cures Act change.
- Review debt-extinguishment details, share-repurchase commitments and the company’s capacity to fund buybacks and dividends alongside debt service and business investment.